Showing results (201-210 of 553) with videos related to
Sort By:
Pageof 56
Drugs in Context|June 14, 2019
Efficacy and safety of lesinurad for the treatment of hyperuricemia in goutFernando Pérez-Ruiz, Tim Jansen, Anne-Katrin Tausche, et al.Drugs in Context|April 20, 2023
Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: a case reportTanyaporn ChantarojanasiriDrugs in Context|April 23, 2021
Selective IL-13 inhibitors for the treatment of atopic dermatitisFrancisca Gonçalves, Egídio Freitas, Tiago TorresDrugs in Context|August 22, 2020
Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: new insights for an accurate descriptionPaolo D'Agostino, Alan Kent, Eric Sharp, et al.Drugs in Context|April 3, 2015
Clinical factors, including All Patient Refined Diagnosis Related Group severity, as predictors of early rehospitalization after COPD exacerbationMelissa H Roberts, Douglas W Mapel, Ann Von Worley, et al.Drugs in Context|April 3, 2015
Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USAAllicia C Girvan, Gebra C Carter, Li Li, et al.Drugs in Context|February 7, 2015
Willingness of European healthcare workers to undergo vaccination against seasonal influenza: current situation and suggestions for improvementGeorge KassianosDrugs in Context|March 14, 2015
Cachexia & debility diagnoses in hospitalized children and adolescents with complex chronic conditions: evidence from the Kids' Inpatient DatabaseBryce A Van Doren, Debosree Roy, Joshua M Noone, et al.Drugs in Context|January 17, 2014
Hemodynamic effect of avanafil and glyceryl trinitrate coadministrationDennis Swearingen, Ajay Nehra, Susie Morelos, et al.Drugs in Context|January 17, 2014
Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best?Eva Vivian, Chelsea MannebachPageof 56